Study Assessments

MN Mina Ekrami Noghabi
MS Mohammad Jafar Saffar
SR Shaghayegh Rezai
HS Hana Saffar
HS Hiva Saffar
FH Fatemeh Hosseinzadeh
AG Aliasghar Nadi Ghara
MR Mohammad Sadegh Rezai
request Request a Protocol
ask Ask a question
Favorite

The objective of this study was to determine antibody seroprotection rates (anti-HBs, anti-Hib PRP, anti-diphtheria toxoid, antitetanus toxoid, and anti-Bordetella pertussis) and calculating geometric mean concentrations (GMC) before vaccination and 4 weeks after the third dose.

Antibody titers were measured by ELISA quantitative kits as follows: Diphtheria (Eurofins Co., with seroprotection defined as antibody concentration <0.01 IU/mL considered as unimmune, 0.01–0.1 IU/mL requiring booster dose and >0.1 IU/mL immune); Tetanus (Eurofins Co., <0.1 IU/mL unimmune, 0.1–1 IU/mL requiring control after 1 to 2 years, 1–5 IU/mL requiring control after 2-4 years and >5 IU/mL requiring control after 4–8 years); Pertussis (Eurofins co., <16 IU/mL unimmune, 16–24 IU/mL borderline and > 24 IU/mL immune); HepB (Diapro Co, <10 IU/mL unimmune, and >10 IU/mL immune); Hib (Demeditec Co, <0.15 IU/mL unimmune, and >0.15 IU/mL immune).

Serum isolated from blood samples were stored at a temperature of−20 °c and analyzed after collection.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

0/150

tip Tips for asking effective questions

+ Description

Write a detailed description. Include all information that will help others answer your question including experimental processes, conditions, and relevant images.

post Post a Question
0 Q&A